Introduction {#s1}
============

Approximately 12.7 million new cases of cancer, and 7.6 million cancer-related deaths occurred in 2008, which indicated global burden of cancer continues to aggravate [@pone.0056722-Jemal1]. Prevention and diagnosis of cancer have become one of the most important challenges of the world. Potent markers for screening high-risk populations are urgently needed for early detection and preventive actions. The development of cancer is a complicated biological process, which is involved with multi-gene mutations and multiple factors, while the individual hereditary background may be the primarily determined risk of cancer susceptibility. The interaction between genetic susceptibility genes with environmental factors and metabolism dysfunction throughout the body plays an important role in the development of cancer [@pone.0056722-Lichtenstein1]. The glutathione S-transferase family (GSTs), which are composed of four major groups including GSTA (α), GSTM1 (μ), GSTT1 (θ), and GSTP1 (π), are phase II detoxifying enzymes that catalyze a variety of reduced glutathione-dependent reactions with electrophilic substrates [@pone.0056722-Hayes1]. Based on the catalytic activity, GSTs metabolize carcinogens and toxins to reduce damage of DNA as a suppressor of carcinogenesis. The risk of cancer is correlated with exposure to xenobiotics or endogenous substances, which may be modified in metabolic detoxification activities by genetic variation [@pone.0056722-Medeiros1]. It is well known that deletion variants of the GSTM1, GSTT1 and GSTP1 loci could result in loss of functional activity. Hendersonet *et al.* [@pone.0056722-Henderson1] found that GSTP1 null mice, disposed with carcinogen polycyclic aromatic hydrocarbons, had a highly significantly increased risk of skin cancer, anddemonstrated that GSTP1 may be an important determinant in cancer susceptibility. Chromosomal polymorphisms in genes involved in DNA repair, cell cycle control, apoptosis or metabolic enzymes may determine individual susceptibility to cancer [@pone.0056722-Beckman1].

Variants of prevalent allele in every GSTs gene may lower the efficiency of detoxification and aggravate the susceptibility to cancer. It was identified that there are two single nucleotide polymorphisms in GSTP1 that lead to changes in amino acids. One at nucleotide 313 (codon 104) in exon 5 (rs1695) has an A to G transition, which results in an amino acid change from isoleucine (*Ile*) to valine (*Val*). The other has a C to T transition in nucleotide 341 (codon 113) in exon 6 (rs1138272) which results in an amino acid change from alanine (*Ala*) to valine (*Val*) **([Figure S1](#pone.0056722.s001){ref-type="supplementary-material"})**. This two loci were reported to cause minimal catalytic activity in individuals who carry one or more copies of the allele G or T [@pone.0056722-Strange1], [@pone.0056722-AliOsman1].

A large number of studies have investigated the role of GSTP1 polymorphism in the etiology of cancer of various organs, including lung, breast, colorectal, bladder, prostate and so on. However, most of these studies contained small number of subjects, and the results of these studies remain conflicting rather than conclusive. In recent years, plenty of meta-analysis studies were extensively carried out to quantitatively evaluate the association between GSTP1 and cancer susceptibility. As a consequence, statistically significant increased risk was found between GSTP1 313A\>G and breast cancer [@pone.0056722-Sergentanis1], esophageal cancer [@pone.0056722-Bull1], bladder cancer [@pone.0056722-Kellen1], leukemia [@pone.0056722-Das1] and other cancers. Nevertheless, no pooled evaluation on GSTP1 341C\>T has been performed yet. In light of the ubiquity of 341C\>T polymorphism and the critical role of GSTP1 in the carcinogenic process, we performed a meta-analysis on all eligible case-control studies to estimate the cumulative cancer risk of this polymorphism, and quantitatively analyze the potential influencing factors, with an expectation to provide the most comprehensive evidence for the relationship between this variant and cancer susceptibility.

Materials and Methods {#s2}
=====================

Search Strategy {#s2a}
---------------

We searched the PubMed, Embase, ISI Web of Knowledge and China National Knowledge Infrastructure for all articles of the association between GSTP1 341C\>T polymorphism and cancer risk. The following terms were used in various combinations in this search: (\"glutathione S-transferase P1\" OR \"GSTP1\") AND (\"polymorphism\" OR \"variant\" OR \"variation\") AND (\"neoplasm\" OR \"cancer\" OR \"carcinoma\" \[last search was updated on August 30, 2012\]). All qualified studies were retrieved, and their references were manually checked for additional related publications. Review articles and references of other relevant studies identified were hand-searched as well to search for extra eligible studies. This search strategy was performed iteratively until no further pertinent article was found. Only published studies with full-text articles were included, without language limited. Non-Chinese or non-English articles were translated by Google Translate. When overlapping data on the same subjects were included in more than one publication, only the one with the larger sample size was included in this meta-analysis.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

Eligible studies in the current meta-analysis had to meet all the following criteria: (a) evaluating the association between GSTP1 Ala114Val polymorphism and cancer risks, (b) using a case-control design, (c) sufficient data of genotypes (CC, CT and TT) were presented with estimated odds ratios (ORs) and 95% confidence intervals (CIs). The major exclusion criteria were: (a) genotype distribution of the control population was deviated from Hardy-Weinberg equilibrium (HWE), (b) family-based control or lack of the control group, (c) duplicated studies.

Data Extraction {#s2c}
---------------

Data were independently extracted in duplicate by two investigators (Shengxin Huang, Feixiang Wu) using a standard protocol and data-collecting form according to the inclusion criteria. Original extraction data were checked by another investigator (Min Luo), and any disagreement was resolved by discussion among the three investigators. The following information was collected from each study: first author\'s surname, year of publication, country, and ethnicity of the study population, cancer types, and source of control groups, genotyping methods, and frequency of genotypes in both groups. Diverse ethnicity descents were categorized as Asian, African, and Caucasian. If a study was impossible to separate participants according to such phenotypes, the group reported was termed as \'\'mixed ethnicity\'\'. For studies which included subjects of diverse ethnic groups or cancer types, data were extracted separately if possible.

Quality Assessment {#s2d}
------------------

We developed a quality assessment scale ([**Table 1**](#pone-0056722-t001){ref-type="table"}), which was modified from previous studies [@pone.0056722-Liu1]--[@pone.0056722-Gao1], to evaluate the quality of eligible studies. Three reviewers (Min Luo, Liang Ma, Kefeng Gao) independently assessed the quality of studies according to the scale for quality assessment. Any disagreement was resolved by discussion among reviewers. The evaluation mainly focused on representativeness of both cases and controls, specimens of cases for determining genotypes, quality control of genotyping method, sample size. Total score ranged from 0 (worst) to 12 (best). Reports scoring ≥9 (≥75%) were classified as \'\'high-quality\'\', scoring 6--8 (50%--75%) as \'\'moderate-quality\'\', \<50% as \"low-quality\".

10.1371/journal.pone.0056722.t001

###### Scale for quality assessment.

![](pone.0056722.t001){#pone-0056722-t001-1}

  Parameter                                                Score
  ------------------------------------------------------- -------
  **1. Source of cases**                                  
  Selected from population or cancer registry                2
  Selected from oncology department or cancer institute      1
  No description                                             0
  **2. Representativeness of controls**                   
  Population-based                                           2
  Population-hospital mixed                                 1.5
  Hospital-based                                             1
  No description                                             0
  **3. Diagnosis of cancer**                              
  Histological or pathologically confirmed                   2
  Patient medical record                                     1
  No description                                             0
  **4. Specimens of cases for genotyping**                
  Peripheral blood or normal tissues                         2
  Tumor tissues or exfoliated cells                          1
  No description                                             0
  **5. Quality control of genotyping**                    
  Different genotyping assays confirmed the result           2
  Quality control by repeated assay                          1
  No description                                             0
  **6. Total sample size**                                
  \>1000                                                     2
  200--1000                                                  1
  \<200                                                      0

Statistics Method {#s2e}
-----------------

Firstly, the allelic frequency was calculated, and the observed genotype frequencies of the GSTP1 341C\>T polymorphism were assessed for Hardy-Weinberg equilibrium using χ^2^ test in the control group in each study. The strength of the association between the GSTP1 341C\>T polymorphism and cancer risk was assessed by calculating ORs with 95% CIs. The overall pooled analysis was performed for homozygote comparison (TT versus CC), heterozygote comparison (CT versus CC), dominant model (TT/CT versus CC) and the recessive model (TT versus CT/CC), respectively. Comparison of the various subjects, stratified analyses were processed according to ethnicity, source of controls, sample size, matched control, quality score and cancer types (if one cancer type contained less than two individual studies, it would be combined into other cancers group). To achieve sufficient statistical power, we only conducted the meta-analysis on cancer types with more than three studies. Otherwise, we merged the studies into the \'\'other cancer\'\' group. The significance of the pooled ORs was determined by the Z-test and *P*\<0.05 was considered as statistically significant. We also computed the power of the selected studies, in order to assess the probability of detecting an association between this polymorphism and cancer at the 0.05 level of significance, assuming genotypic risks of 1.2, 1.5 and 2.0.

The heterogeneity of studies was assessed through the Cochran\'s Q-test and the *I* ^2^ test. If *P*\<0.1 or *I* ^2^\>50%, it was considered substantial heterogeneity among studies, and the random-effects model (the DerSimonian and Laird method) was applied as the preferred method for estimating the summary ORs and 95% CIs; the fixed-effects model (the Mantel-Haenszel method) was used when there was without substantive heterogeneity. Moreover, sensitivity analysis, by which a single study in the meta-analysis was deleted each time to determine the influence of the individual data set for the overall pooled OR, was performed to assess the stability of the results. To assess the potential publication bias, visual inspection of Begger\'s funnel plot symmetry [@pone.0056722-Egger1] was performed. Egger\'s test was also conducted to analyze the publication bias statistically. The meta-analysis was conducted using Stata software (version 12.0; StataCorp LP, College Station, Texas), with all the *P* values were two-sided. Power was calculated using the power and sample size calculation software PS version 3.0 (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>). [@pone.0056722-Dupont1].

Results {#s3}
=======

Characteristics of Studies {#s3a}
--------------------------

As showed in [**Figure 1**](#pone-0056722-g001){ref-type="fig"}, 46 studies exploring the relationship between GSTP1 polymorphisms and cancer susceptibility were identified. After reading the full texts, 21 studies were excluded because they did not provide allele frequencies, which were needed for OR calculation, deviated from the HWE, family-based control or lack of the control group. In addition, one qualified study was identified from review articles and bibliography through hand searching. Finally, a total of 26 eligible publications with 28 case-control studies [@pone.0056722-AlDayel1]--[@pone.0056722-1] met the preset inclusion criteria, in which 13249 cases and 16798 controls were included for the pooled analysis. All studies\' characteristics were summarized in [**Table 2**](#pone-0056722-t002){ref-type="table"}. All the studies were published in English except for one [@pone.0056722-Marciniak1]. This meta-analysis included seven colorectal cancer studies, six lung cancer studies, four breast cancer studies, three upper digestive tract cancer studies, two thyroid cancer studies, and six other cancer studies (including lymphoma, melanoma *etc.*). There were 14 population-based studies, 13 hospital-based studies and one population-hospital mixed study [@pone.0056722-Canova1]. Nineteen of 28 studies were conducted in Caucasians; four studies were conducted in Asians [@pone.0056722-AlDayel1], [@pone.0056722-Ebrahimkhani1], [@pone.0056722-Siraj1], [@pone.0056722-Wang1]; one study was conducted in Africans [@pone.0056722-VanEmburgh1], and four studies of mixed population [@pone.0056722-Harris1], [@pone.0056722-Moore1], [@pone.0056722-Yang1].

![Studies identified with criteria for inclusion and exclusion.](pone.0056722.g001){#pone-0056722-g001}

10.1371/journal.pone.0056722.t002

###### Characteristics of studies included in the meta-analysis.

![](pone.0056722.t002){#pone-0056722-t002-2}

  Author              Publication year     Country      Ethnicity   Cancer type   Control source   Genotyping methods        Matching criteria         n(case)   n(control)    MAF    Power(%)[\*](#nt102){ref-type="table-fn"}   Quality score          
  ------------------ ------------------ -------------- ----------- ------------- ---------------- -------------------- ------------------------------ --------- ------------ ------- ------------------------------------------- --------------- ------- -----
  Al-Dayel                  2008         Saudi Arabia     Asian      Lymphoma           PB              PCR-RFLP                  Age, sex               145        510       0.126                     11.4                          36.9        80.5     5
  Landi                     2005            Spain       Caucasian   Coleractal          HB                APEX                       NA                  360        325       0.055                      8.6                          25.6        65.8     5
  Barnette                  2004             USA        Caucasian    Leukaemia          HB               AS-PCR                      NA                  170        288       0.075                      8.6                          24.1        60.1     5
  Wadelius                  1999            Sweden      Caucasian    Prostate           PB              PCR-SSCP                    Age                  171        148       0.095                      7.7                          20.4        53.1     6
  Van Emburgh               2008             USA         African      Breast            HB              PCR-SSCP               Age, ethnicity            54          74       0.027                      5.7                           7.6        12.9     6
  Ibarrola-Villava          2012            Spain       Caucasian    Melanoma           HB               TaqMan                    Region                555        359       0.025                      6.8                          16.1        43.5     6
  Ebrahimkhani              2012             Iran         Asian     Coleractal          HB           Pyrosequencing                  NA                  73          95       0.063                      6.3                          11.2        25.1     6
  Marciniak                 2006            Poland      Caucasian     Thyroid           HB              PCR-RFLP                     NA                  103         53       0.113                      5.9                          11.2        27.3     6
  Siraj                     2008         Saudi Arabia     Asian       Thyroid           PB              PCR-RFLP                    Age                  40         510       0.126                      8.2                          18.8        43.3     7
  Van Emburgh               2008             USA        Caucasian     Breast            HB              PCR-SSCP               Age, ethnicity            386        385       0.064                      9.8                          32.1        77.3     7
  Saarikoski                1998           Finland      Caucasian      Lung             PB              PCR-RFLP                     NA                  206        293       0.090                      9.5                          29.2        70.9     8
  Jiao                      2007             USA        Caucasian   Pancreatic          HB            MassCode PCR                Age, sex               335        298       0.096                     10.6                          36.6        82.7     8
  Kim                       2008           Germany      Caucasian     Breast            HB            MALDI-TOF MS                  Age                  596        609       0.076                     14.0                          52.5        95.4     8
  Zienolddiny               2008            Norway      Caucasian      Lung             PB                APEX               Age, sex, smoking           319        381       0.066                      9.7                          30.8        74.4     8
  Wang                      2011            India         Asian     Coleractal          PB              PCR-RFLP                  Age, sex               302        291       0.050                      7.9                          21.4        56.2     8
  Murphy                    2007           Ireland      Caucasian   Oesophageal         PB           Multiplex PCR                Age, sex               207        223       0.078                      8.3                          23.3        59.8     9
  Küry                      2008            France      Caucasian   Coleractal          PB               TaqMan                   Age, sex              1023        1121      0.073                     20.8                          75.7        99.8     9
  García-Closas             2005            Spain       Caucasian     Bladder           HB               TaqMan         Age, sex, ethnicity, region     1083        1007      0.047                     14.9                          56.9        97.2     9
  MARIE-GENICA              2010           Germany      Caucasian     Breast            PB            MALDI-TOF MS              Age, region             3148        5487      0.086                     66.5                          100.0       100.0    9
  sorensen                  2004           Danmark      Caucasian      Lung             PB              PCR-RFLP                     NA                  253        266       0.086                      9.3                          28.9        71.3     9
  Northwood                 2010              UK        Caucasian   Coleractal          PB               TaqMan                      NA                  308        296       0.111                     11.2                          38.9        85.5     9
  Yang                      2004             USA          Mixed        Lung             PB               TaqMan                      NA                  229        229       0.092                      9.0                          27.3        68.3     9
  Landi                     2007            Italy       Caucasian       MPM             PB                APEX                       NA                  88         391       0.051                      7.8                          17.1        39.9     9
  Canova                    2009            Italy       Caucasian      UDTC           Miexed              APEX          Age, sex, ethnicity, region     1501        1449      0.073                     26.7                          87.5        100.0   9.5
  wang                      2003             USA        Caucasian      Lung             PB              PCR-RFLP        Age, sex, ethnicity, smoking     579        598       0.075                     13.7                          51.1        94.8    10
  Moore                     2005             USA          Mixed     Coleractal          HB               TaqMan                Sex, ethnicity            700        714       0.085                     16.8                          63.4        98.6    10
  Harris                    1998          Australia       Mixed     Coleractal          HB              PCR-RFLP                     NA                  131        199       0.073                      7.6                          18.7        47.2    10
  Harris                    1998          Australia       Mixed        Lung             HB              PCR-RFLP                     NA                  184        199       0.073                      7.8                          20.3        52.6    10

MPM, malignant pleural mesothelioma; UDTC, upper digestive tract cancer; HB, hospital--based control; PB, population-based control; APEX, arrayed primer extension; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSCP, single strand conformation polymorphism; AS, allele-specific; ASO, allele-specific oligonucleotide; MALDI-TOF-MS, matrix-assisted laser desorption/ionization time-of-flight-mass spectrometry; NA: not available.

Power was calculated by the PS software with MAF in controls as the frequency of risk factor and OR was selected with 1.2, 1.5 and 2 as the relative risk.

Generally, the quality of these included studies was satisfactory. Cancers were confirmed by histology or pathology in 78.6% (22/28) studies. Most of the studies described genotyping measures of controls, such as positive and/or negative controls (4/28), blindness to case-control status (5/28), confirmation by different genotyping methods(2/28) and random repetition in 50%(14/28) studies. 60.7% (17/28) studies used matched control population by age, gender, ethnicity or other factors. Most of the included studies adopted rational sample size, and 60.7% (17/28) of all studies were with large sample size (\>500). The total sample size of each group was more than 1000 in seven studies. However, only two studies had statistical power over 80% when we assumed an allelic OR of 1.5. According to the preset Quality Assessment Scale, most of the included studies were identified as \'\'moderate-quality\'\' (13 studies) and \'\'high-quality\'\' (12 studies), only three studies as \"low-quality\". Different genotyping methods were utilized in these studies, including the classical method PCR-RFLP, TaqMan assay, APEX technology, MALDI-TOF MS and other methods in the remaining studies.

Quantitative Synthesis {#s3b}
----------------------

[**Table 3**](#pone-0056722-t003){ref-type="table"} lists the main results of this pooled analysis and [**Figure 2**](#pone-0056722-g002){ref-type="fig"} **and** [**3**](#pone-0056722-g003){ref-type="fig"} show the association of GSTP1 341C\>T polymorphism with cancer risk in the form of forest plots. For the overall analysis, significant association between the risk of cancer and the variant genotypes of GSTP1 341C\>T polymorphism was found in homozygote comparison (TT versus CC: *P* = 0.012, OR = 1.40, 95% CI: 1.08--1.81, *P* ~het.~ = 0.575), and recessive model (TT versus CT/CC: *P* = 0.012, OR = 1.40, 95% CI: 1.08--1.81, *P* ~het.~ = 0.562). However, no significant association was found in heterozygote comparison (CT versus CC) nor the dominant model (TT/CT versus CC).

![Forest plot of cancer risk associates with GSTP1 341C\>T polymorphism under homozygote comparison (TT versus CC) in different ethnicity.\
African ethnic is omitted due to the insufficient data. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study specific weight. The diamond represents the pooled OR and 95% CI.](pone.0056722.g002){#pone-0056722-g002}

![Forest plot of cancer risk associate with GSTP1 341C\>T polymorphism under dominant model (TT/CT versus CC) of different types of cancers.\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study specific weight. The diamond represents the pooled OR and 95% CI.](pone.0056722.g003){#pone-0056722-g003}
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###### Stratified analyses of the GSTP1 341C\>T polymorphism on cancer risk.

![](pone.0056722.t003){#pone-0056722-t003-3}

  Variables                 N                      TT versus CC                                       CT versus CC                                     TT/CT versus CC (Dominant model)                                                               TT versus CT/CC (Recessive model)                                                                                                                               
  ------------------------ ---- -------------------------------------------------- --------------------------------------------------- ------ -------------------------------------------------- --------------------------------------------------- ----------------------------------- -------------------------------------------------- ------- ------ -------------------------------------------------- ------- ------
  **Overall**               28                 **1.40(1.08--1.81)**                                       0.575                         0.0                    1.04(0.97--1.11)                                         0.305                                       10.6                                  1.06(0.99--1.13)                   0.281   12.3                 **1.40(1.08--1.81)**                 0.562   0.0
  **Cancer types**                                                                                                                                                                                                                                                                                                                                                                                                    
  Colorectal cancer         7                    0.91(0.48--1.71)                                         0.349                         10.5                   1.01(0.87--1.17)                                         0.220                                       27.3                                  1.00(0.87--1.16)                   0.143   37.4                   0.90(0.48--1.71)                   0.375   7.0
  Lung cancer               6                    1.96(0.97--3.92)                                         0.274                         21.2                 **1.21(1.02--1.45)**                                       0.197                                       31.8                                **1.25(1.05--1.48)**                 0.114   43.8                   1.90(0.95--3.82)                   0.292   18.7
  UDTC                      3                    1.11(0.54--2.28)                                         0.605                         0.0                    0.95(0.79--1.14)                                         0.245                                       28.8                                  0.96(0.80--1.14)                   0.282   21.0                   1.11(0.54--2.29)                   0.593   0.0
  Breast cancer             4                    1.29(0.84--1.99)                                         0.902                         0.0                    1.04(0.93--1.16)                                         0.730                                        0.0                                  1.05(0.94--1.17)                   0.724   0.0                    1.28(0.83--1.98)                   0.908   0.0
  Thyroid cancer            2                   3.45(0.89--13.29)                                         0.929                         0.0                    0.85(0.47--1.55)                                         0.786                                        0.0                                  1.06(0.61--1.83)                   0.954   0.0                   3.56(0.93--13.69)                   0.913   0.0
  Other cancer              6                    1.94(0.98--3.83)                                         0.505                         0.0                    1.05(0.87--1.28)                                         0.306                                       16.7                                  1.10(0.91--1.32)                   0.665   0.0                  **1.98(1.01--3.91)**                 0.447   0.0
  **Ethnicity**                                                                                                                                                                                                                                                                                                                                                                                                       
  African                   1                           NC                          1.48 (0.33--6.65)[a](#nt104){ref-type="table-fn"}                                                             1.48 (0.33--6.65)[a](#nt104){ref-type="table-fn"}                                                                                           NC                                                                      
  Asian                     4                  **3.42(1.56--7.47)**                                       0.997                         0.0    1.19(0.72--1.98)[b](#nt105){ref-type="table-fn"}                         0.052                                       61.2                                  1.24(0.94--1.64)                   0.120   48.6                 **3.49(1.59--7.63)**                 0.998   0.0
  Caucasian                 19                   1.18(0.88--1.58)                                         0.613                         0.0                    1.05(0.98--1.13)                                         0.349                                        8.7                                  1.06(0.99--1.14)                   0.241   17.5                   1.17(0.88--1.57)                   0.631   0.0
  Mixed                     4                    2.24(0.91--5.51)                                         0.826                         0.0                    0.91(0.74--1.13)                                         0.932                                        0.0                                  0.96(0.77--1.18)                   0.926   0.0                    2.28(0.93--5.60)                   0.828   0.0
  **Source of controls**                                                                                                                                                                                                                                                                                                                                                                                              
  Population-based          14                 **1.45(1.05--1.99)**                                       0.206                         22.9                   1.04(0.96--1.14)                                         0.203                                       23.1                                  1.06(0.98--1.16)                   0.163   27.2                 **1.45(1.05--1.99)**                 0.196   23.8
  Hospital-based            13                   1.52(0.89--2.58)                                         0.882                         0.0                    1.06(0.93--1.20)                                         0.373                                        7.3                                  1.08(0.95--1.22)                   0.422   2.5                    1.52(0.89--2.57)                   0.879   0.0
  **Matched control**                                                                                                                                                                                                                                                                                                                                                                                                 
  Yes                       17                 **1.42(1.07--1.89)**                                       0.468                         0.0                    1.06(0.98--1.14)                                         0.133                                       28.3                                  1.07(0.99--1.15)                   0.137   27.9                 **1.42(1.07--1.89)**                 0.444   0.7
  No                        11                   1.28(0.68--2.42)                                         0.510                         0.0                    0.97(0.82--1.14)                                         0.728                                        0.0                                  0.98(0.83--1.16)                   0.669   0.0                    1.29(0.68--2.44)                   0.518   0.0
  **Quality score**                                                                                                                                                                                                                                                                                                                                                                                                   
  ≥9                        12                   1.08(0.79--1.48)                                         0.700                         0.0                    1.03(0.95--1.11)                                         0.670                                        0.0                                  1.03(0.96--1.11)                   0.699   0.0                   1.078(0.79--1.48)                   0.697   0.0
  6--8                      13                 **2.82(1.56--5.09)**                                       0.982                         0.0    1.14(0.93--1.39)[b](#nt105){ref-type="table-fn"}                         0.093                                       37.3                  1.21(0.99--1.47)[b](#nt105){ref-type="table-fn"}   0.080   39.1                 **2.78(1.54--5.03)**                 0.986   0.0
  ≤5                        3    1.09(0.15--7.81)[b](#nt105){ref-type="table-fn"}                         0.116                         53.5                   0.89(0.67--1.19)                                         0.588                                        0.0                                  0.94(0.71--1.25)                   0.954   0.0    1.10(0.14--8.36)[b](#nt105){ref-type="table-fn"}   0.103   56.0
  \>5                       25                 **1.36(1.04--1.79)**                                       0.715                         0.0                    1.05(0.98--1.13)                                         0.257                                       14.5                                  1.07(0.99--1.14)                   0.186   19.9                 **1.36(1.03--1.78)**                 0.729   0.0

UDTC, upper digestive tract cancer; Phet., *P* value of Q -test for heterogeneity test; NC, no insufficient data for calculation; N, number of studies for comparison; The figures given in bold indicate statistically significant values.

OR adjusted for age, family history, smoking history, age of menarche, age of first birth and body mass index according to the author.

Random-effect model was used.

In a stratified analysis by cancer type, significant risk was observed in lung cancers in heterozygote comparison (CT versus CC: *P* = 0.033, OR = 1.21, 95% CI: 1.02--1.45, *P* ~het.~ = 0.197) and dominant model (TT/CT versus CC: *P* = 0.013, OR = 1.25, 95% CI: 1.05--1.48, *P* ~het.~ = 0.114). Interestingly, statistically significantly ascending cancer risk was also observed in \'\'other cancers\'\' in the recessive model (TT versus CT/CC: *P* = 0.048, OR = 1.98, 95% CI: 1.01--3.91, *P* ~het.~ = 0.447). No significant association was found between this polymorphism and thyroid cancer, breast cancer, upper digestive tract cancers and colorectal cancer. In subgroup analysis according to ethnicity, significantly increased risk was found in the Asian population (TT versus CC: *P* = 0.002, OR = 3.42, 95% CI: 1.56--7.47, *P* ~het.~ = 0.997; TT versus CT/CC: *P* = 0.002, OR = 3.49, 95% CI: 1.59--7.63, *P* ~het.~ = 0.998), but this association was not found in the African, Caucasian and mixed population. After stratified analysis by the source of controls, significantly increased risk was observed in population-based studies (TT versus CC: *P* = 0.023, OR = 1.45, 95% CI: 1.05--1.99, *P* ~het.~ = 0.206; TT versus CT/CC: *P* = 0.024, OR = 1.45, 95% CI: 1.05--1.99, *P* ~het.~ = 0.196). Moreover, this association was found in those studies with matched controls (TT versus CC: *P* = 0.015, OR = 1.42, 95% CI: 1.07--1.89, *P* ~het.~ = 0.468; TT versus CT/CC: *P* = 0.016, OR = 1.45, 95% CI: 1.07--1.89, *P* ~het~ = 0.444). According to the quality assessment, this association was found in those \'\'moderate-quality\'\' studies (TT versus CC: *P* = 0.001, OR = 2.82, 95% CI: **1.56--5.09**, *P* ~het.~ = 0.982; TT versus CT/CC: *P* = 0.001, OR = 2.78, 95% CI: 1.54--5.03, *P* ~het.~ = 0.986), and this similar result was also detected when three \'\'low-quality\'\' studies were excluded (TT versus CC: *P* = 0.023, OR = 1.36, 95% CI: 1.04--1.79, *P* ~het.~ = 0.715; TT versus CT/CC: *P* = 0.029, OR = 1.36, 95% CI: 1.03--1.78, *P* ~het.~ = 0.729).

Heterogeneity and Sensitivity Analysis {#s3c}
--------------------------------------

For the overall comparisons, no significant heterogeneity among studies was observed (the four genetic model comparison all *P* ~het.~\>0.1), which suggested that there was no substantial heterogeneity between studies, except significant heterogeneity in the stratified analysis according to ethnicity (CT versus CC: *P* ~het.~ = 0.052, *I* ^2^ = 61.2%), for which the random-effect model was conducted in the pooled analysis. In the sensitivity analyses, the influence of each study on the pooled OR was checked by repeating the meta-analysis while omitting each study, one at a time. The corresponding pooled ORs were not materially altered, indicating that our results were statistically robust (**[Table S1](#pone.0056722.s002){ref-type="supplementary-material"}**).

Publication Bias {#s3d}
----------------

Begger\'s funnel plot and Egger\'s test were performed to assess the publication bias of articles. As it showed in [**Figure 4**](#pone-0056722-g004){ref-type="fig"} **and** [**5**](#pone-0056722-g005){ref-type="fig"}, the shapes of the funnel plots did not reveal any evidence of an obvious asymmetry in all comparison models. Moreover, Egger\'s test was used to provide statistical evidence of funnel plot symmetry. The results still did not show any evidence of publication bias (*t* = 0.99, *P* = 0.330 for TT versus CC; *t* = 0.41, *P* = 0.688 for CT versus CC; *t* = 0.99, *P* = 0.332 for dominant model; *t* = 0.96, *P* = 0.346 for recessive model).

![Begg\'s funnel plot for publication bias test (TT versus CC).\
Each point represents a separate study for the indicated association. LogOR, natural logarithm of OR. Horizontal line, mean effect size.](pone.0056722.g004){#pone-0056722-g004}

![Begg\'s funnel plot for publication bias test (TT/CT versus CC).\
Each point represents a separate study for the indicated association. LogOR, natural logarithm of OR. Horizontal line, mean effect size.](pone.0056722.g005){#pone-0056722-g005}

Discussion {#s4}
==========

As detoxifying enzyme, glutathione S-transferase plays an important role in protecting cells from cytotoxic and carcinogenic agents in the defense system. The GSTP1 gene is located on chromosome 11q13, and previous studies have indicated that it was widely expressed but predominantly in normal epithelial cells, such as the respiratory tract system, digestive system, and urinary system [@pone.0056722-Terrier1]. Exon 5 (313A\>G) and exon 6 polymorphisms (341C\>T) were reported that they could result in decreased conjugating activity [@pone.0056722-AliOsman1]. The GSTP1 313A\>G polymorphism was shown to be a predisposing risk factor for a number of human malignancies. Accordingly, we speculated that GSTP1 341C\>T polymorphism might also be a risk factor in the genesis and development of cancer. Previous conclusions of numerous studies on the association between the GSTP1 341C\>T polymorphism and cancer risk remain conflicting and contradictory. The inconsistent results are possibly because of a slight effect of the polymorphism on cancer risk or the relatively low statistical power of published studies. Consequently, meta-analysis is needed to provide a quantitative approach for combining the different results.

The present meta-analysis, which included 13249 cases and 16798 controls from 26 publications with 28 case-control studies, explored the relationship between the 341C\>T polymorphism and cancer risk. For overall comparison of pooled ORs, significantly increased risk was observed in homozygote comparison (TT versus CC) and the recessive model (TT versus CT/CC), without significant between-study heterogeneity. These results indicated that GSTP1 341C\>T polymorphism may increase cancer risk, especially in individuals with mutant allele homozygous TT genotype.

Previous studies have proved that GSTP1 was variably expressed in malignant tumor tissues with a low level in lymphoma and breast cancer, while over-expressed were found in lung cancer, head and neck tumors and colon cancer [@pone.0056722-Moscow1]. GSTP1 exert varying effects on different organs, and the carcinogenic mechanism difference may account for varied cancer risk. Our meta-analysis provide evidence that the variant GSTP1 341C\>T may enhance individual susceptibility to lung cancer when special cancer was concerted. This result demonstrates the disparate distribution of GSTP1 in different sites, and the over-expressed GSTP1 may be a risk of cancer. Furthermore, genetic variability in the individual response to carcinogens might modify the susceptibility to cancer [@pone.0056722-Chan1]. Van Emburgh *et.al* [@pone.0056722-VanEmburgh1]found that the effect of the GSTP1 SNPs appeared to be modulated by smoking history in a case-control study, leading to a 2-fold increase in breast cancer risk, which was also observed in smokers with the 341T allele. Meanwhile, it\'s worth noting that statistically increased risk was observed in \'\'other cancer\'\', which was combined with a number of single studies with different cancer types, implying that significant association may really exist. But due to the low statistical power, further well-designed studies with larger sample size based on specific cancer need to be carried out to re-examine this correlation.

In the stratified analysis based on ethnicity, no significant risk of cancer was found except for the Asian population. We simply presented the ORs of the one study of African population according to the original result and adjusted by some factor, such as the age, and smoking history [@pone.0056722-VanEmburgh1]. A total of 19 studies(11391 cases and 13977 controls), which were determined to be adequate for supporting the observed result, investigated the relationship between this polymorphism and cancer risk among Caucasian, but no significant risk was found. The pooled analysis of the Asian population, including four single studies with 1966 subjects, reached a 78% statistical power when we assumed an allelic OR of 1.5. A significantly elevated risk of cancer was discovered in the homozygote comparison and recessive model of the Asian population; the pooled ORs are 3.42- and 3.49-fold of the referenced genotype. Our results demonstrated that there was a moderate association between the GSTP1 341C\>T polymorphism and cancer risk in Asian population. Although the reason for these discrepancies is not positively known, some possibilities should be considered, such as the differences in the underlying environment-gene interaction and lifestyle. Nevertheless, additional larger sample size study or genome-wide association study is warranted for further validation of this finding.

When stratifying the source of controls, a weak strength was observed in population-based control studies (OR = 1.45, 95% CI: 1.05--1.99 for both homozygote comparison and recessive model), but not in the hospital-based control studies. After attentive observation of the strength of association, it was found that not only the ORs were closed to the overall comparison, but also in the same genetic model. The hospital-based control studies may have an inherent selection bias since the controls may not be representative of the general population, particularly as the controls may be associated with the disease-related conditions, such as benign inflammatory lesions, which were the confounding factors for investigation. Analogously, evidently increased cancer risk was detected in matched control studies, but not in those studies without matched control. The matching criteria of these studies were mostly matched with age, sex and ethnic. In addition, some matched with region and lifestyle, for example, smoking or alcohol consumption. Apparently, matching criteria play an important role in genetic polymorphism and disease association studies, as it may avoid selection bias for control and reduce the impact of potential confounding factors on the investigation. All the studies were divided into three levels in accordance with the quality assessment scale. Significantly increased cancer risk was detected in the \'\'moderate-quality\'\' studies, but not the \'\'high-quality\'\' studies. There were three Asian population studies in this \'\'moderate-quality\'\' level, which may account for this phenomenon. It was noteworthy that the pooled ORs were not materially changed from the result of overall comparison, when removed three \'\'low-quality\'\' studies. It\'s indicated that the overall comparison results were statistically robust when excluding the low-quality studies.

To the best of our knowledge, this is the first and the most comprehensive meta-analysis undertaken so far for quantitative analyses between GSTP1 341C\>T polymorphism and the risk of cancer. However, in interpreting the outcome of this meta-analysis, some limitations need to be addressed. Firstly, there was insufficient data on the African population in this meta-analysis. Secondly, this meta-analysis was based on unadjusted evaluation, and original data shortage limited our further evaluation of potential gene-environment interactions. In order to provide a more precise estimation based on adjustment of confounding factors, well-designed studies are warranted by taking potential confounding factors such as smoking and alcohol consumed into account. In spite of these, our meta-analysis still has some advantages. On one hand, all the studies included in the current meta-analysis met our selection criteria, and all the pooled ORs based on no substantial heterogeneity between studies. On the other hand, there was not any publication bias detected, which indicates that the entire pooled result is robust and authentic. Besides, the subject number of more than 30 000 in the published studies is sufficient for a comprehensive analysis, which dramatically increases the statistical power of the analysis.

In conclusion, our meta-analysis suggests that the GSTP1 341C\>T polymorphism may implicate genetic susceptibility to cancer. Since only one study from the African population and four studies from the Asian population, it is critical that a larger sample size and well-designed multi-center studies based on these two ethnic groups should be performed to further re-evaluate the association. Furthermore, investigation of the impact of gene-gene and gene-environment interactions on the GSTP1 341C\>T polymorphism and cancer risk is necessary for providing a better comprehensive understanding of the association.
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